To further reduce medication non-adherence among schizophrenic patients, a new formulation of paliperidone palmitate given every 3 months (PP-3M) was recently approved. 1 A review on the safety and ...
This was a 12-week, multicenter, open-label, prospective clinical study conducted in inpatients and outpatients. Throughout the study flexible dosing in the range 3–12 mg/day was used so as to allow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback